Mosaic ImmunoEngineering (CPMV) Long-Term Debt Issuances (2010 - 2024)
Mosaic ImmunoEngineering (CPMV) posted quarterly Long-Term Debt Issuances of $200000.0 for Q4 2024, up 1233.33% quarter-over-quarter from $15000.0 in Q3 2024.
Mosaic ImmunoEngineering (CPMV) Long-Term Debt Issuances (2010 - 2024) Analysis & Trends
Mosaic ImmunoEngineering's Long-Term Debt Issuances history runs 4 years deep, the most recent figure standing at $200000.0 for Q4 2024.
- In Q4 2024, Long-Term Debt Issuances changed N/A year-over-year to $200000.0; the TTM figure through Dec 2025 stood at $215000.0 (changed 0.0% YoY), while the FY2024 annual figure was $270000.0, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2024 stood at $200000.0, up from $15000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $525003.0 in Q2 2021, with the low at $15000.0 in Q3 2024.
- The 3-year median for Long-Term Debt Issuances is $270816.0 (2022), against an average of $270408.8.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 200,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Mar 31, 2022 | 341,632.00 |
| Mar 31, 2022 | 341,632.00 |
| Jun 30, 2021 | 525,003.00 |
| Jun 30, 2021 | 525,003.00 |
| Nov 30, 2010 | 2.62 Mn |
| Nov 30, 2010 | 2.62 Mn |
| Aug 31, 2010 | 500,000.00 |
| Aug 31, 2010 | 500,000.00 |